E3 PreliminaryPreliminaryPEM unclearReview-NarrativePeer-reviewedMachine draft
Kynurenine pathway Hypothesis: The nature of the chronic Fatigue syndrome (cFs) Revisited.
Blankfield, Adele · International journal of tryptophan research : IJTR · 2011 · DOI
Quick Summary
This study examines a theory that ME/CFS might be related to problems with how the body processes an amino acid called tryptophan. The body normally breaks down tryptophan through a pathway called the kynurenine pathway, and the researchers suggest that abnormalities in this process could contribute to the symptoms of chronic fatigue syndrome.
Why It Matters
Understanding the biological mechanisms underlying ME/CFS is crucial for developing targeted treatments. If the kynurenine pathway is indeed dysregulated in ME/CFS, it could lead to new biomarkers for diagnosis and novel therapeutic interventions targeting tryptophan metabolism.
Observed Findings
- Tryptophan metabolism dysfunction could theoretically explain multiple ME/CFS symptoms
- The kynurenine pathway produces metabolites that affect immune function and neurological function
- Current literature suggests potential links between tryptophan dysmetabolism and chronic fatigue conditions
Inferred Conclusions
- Abnormal kynurenine pathway function represents a plausible biological mechanism for ME/CFS
- Tryptophan metabolism warrants investigation as a therapeutic target in ME/CFS
- The kynurenine hypothesis could integrate observations of immune and neurological dysfunction in ME/CFS
Remaining Questions
- Are kynurenine pathway metabolites actually elevated or depleted in ME/CFS patient populations compared to healthy controls?
- Do interventions targeting the kynurenine pathway improve ME/CFS symptoms?
- How does any kynurenine pathway dysfunction connect to post-exertional malaise and other distinctive ME/CFS features?
- Which specific enzymes or regulatory points in the pathway are dysregulated?
What This Study Does Not Prove
This study does not provide empirical evidence that the kynurenine pathway is actually abnormal in ME/CFS patients, nor does it establish causation. As a mechanistic hypothesis paper without original patient data, it presents a theoretical framework that requires prospective clinical validation through direct measurements of kynurenine pathway metabolites in ME/CFS populations.
Tags
Symptom:Cognitive DysfunctionFatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:Exploratory Only
Metadata
- DOI
- 10.4137/IJTR.S7898
- PMID
- 22084603
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 10 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →